tricuspid

SOLACI-SBHCI 2023 Scientific Coverage – Day 3

The third day of the Congress started at the Copacabana Arena with the International Live Case held at Nanjing First Hospital, Nanjing, China, which showcased a successful and illustrative step-by-step Transcatheter Coronary Intervention (TCI) angioplasty with circulatory support and optimized results using Intravascular Ultrasound (IVUS) applicability. Following that, Dr. Fei Ye presented Intravascular Imaging and<a href="https://solaci.org/en/2023/08/05/solaci-sbhci-2023-scientific-coverage-day-3/" title="Read more" >...</a>

SOLACI/SBHCI 2023: Scientific Coverage &#8211; Day 2

The second day of the SOLACI/SBHCI 2023 Congress, the largest interventional cardiology meeting in Latin America, organized by the Latin American Society of Interventional Cardiology (SOLACI) and the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI), held in Rio de Janeiro, featured various national and international guests, along with important sessions on the main topics<a href="https://solaci.org/en/2023/08/03/solaci-sbhci-2023-scientific-coverage-day-2/" title="Read more" >...</a>

Scientific Coverage SOLACI-SBHCI 2023

Congress SOLACI-SBHCI 2023 &#8211; Day 1 Summary

Today, the SOLACI SBHCI 2023 Congress, the largest interventional cardiology event in Latin America, organized by the Latin American Society of Interventional Cardiology (SOLACI) and the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI), began in Rio de Janeiro. The event is taking place between August 2nd August 4th at the Windsor Convention Center &amp;<a href="https://solaci.org/en/2023/08/03/congress-solaci-sbhci-2023-day-1-summary/" title="Read more" >...</a>

Is Edge-to-Edge Treatment with PASCAL Effective at 3 Years?

Mitral regurgitation is the most common valvular heart disease. Its cause is most frequently functional or secondary dysfunction (functional mitral regurgitation, FMR) compared with degenerative mitral regurgitation (DMR), which is associated with decreased ventricular function, hospitalization for heart failure, and mortality. While medical treatment is effective over extended periods, a significant number of patients cannot<a href="https://solaci.org/en/2023/07/10/is-edge-to-edge-treatment-with-pascal-effective-at-3-years/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Transcatheter Mitral Valve Replacement vs. Medical Therapy

Mitral valve regurgitation (MR) is a common cause behind heart failure and is associated to hospitalization for heart failure and higher mortality.&nbsp; Transcatheter edge-to-edge repair (TEER), together with guideline-directed medical therapy (GDMT) has been shown beneficial in high risk patients, according to the COAPT study. However, there is a significant group of patients that make<a href="https://solaci.org/en/2023/07/04/transcatheter-mitral-valve-replacement-vs-medical-therapy/" title="Read more" >...</a>

El estudio CULPRIT-SHOCK finalmente se publica en el NEJM y llega para cambiar las guías

Aortic Stenosis and Cardiogenic Shock: Is TAVR an Option?

Cardiogenic shock (CS) in a setting of aortic stenosis is associated with high mortality rates. In consequence, surgery is generally not a possibility for this patient group, and they usually undergo aortic valvuloplasty, resulting in a mortality rate of 33%-50% at 30 days, 70% at one year, and 90% at two years. While transcatheter aortic<a href="https://solaci.org/en/2023/07/04/aortic-stenosis-and-cardiogenic-shock-is-tavr-an-option/" title="Read more" >...</a>

MIL TRAINING MORE MIL: DAY 4 at Favaloro Foundation

&#x25b6; We keep sharing the experience “MIL Train More MIL – SOLACI”, our program on structural heart disease for Latin American Women Interventionists &#x1fa7a; Our scholarship program on structural heart disease continues to thrive in specialized centers in Argentina. &#x1f3e5; Today was Favaloro Foundation’s turn. &#x25b6; Here is the complete scientific program of day 4<a href="https://solaci.org/en/2023/06/30/mil-training-more-mil-day-4-at-favaloro-foundation/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

New Devices for Percutaneous Treatment of Native Aortic Regurgitation: Expanding Horizons

Severe aortic regurgitation (AR) may account for 20% to 30% of all surgical aortic valve replacements (SAVR) and is often associated with aortic stenosis (AS). Transcatheter treatment of these patients is limited due to anatomical factors such as root and annular dilation, large annular dimensions, and less calcification in the valve leaflets to serve as<a href="https://solaci.org/en/2023/06/26/new-devices-for-percutaneous-treatment-of-native-aortic-regurgitation-expanding-horizons/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

TAVR: Does HALT Affect Follow-Up?

Transcatheter aortic valve replacement (TAVR) in low-risk patients has been shown to be superior or noninferior in randomized studies, but the presence of valvular thrombosis, in its different forms, has not been well analyzed, nor is there much information on its impact on evolution. Researchers conducted an analysis of the LTR study that included 200<a href="https://solaci.org/en/2023/06/07/tavr-does-halt-affect-follow-up/" title="Read more" >...</a>

La meseta por la que transcurre la cirugía desde hace varios años

Mitral Valve Surgery after Edge-to-Edge Repair

In last few years, transcatheter edge-to-edge repair (TEER) with MitraClip has been shown safe and effective, both for primary and secondary mitral valve regurgitation (MR), given the increasing interventionist and echocardiographer experience.&nbsp; &nbsp; However, there is a group of patients that require surgery after failed TEER, either because of bad evolution or because device implantation<a href="https://solaci.org/en/2023/05/30/mitral-valve-surgery-after-edge-to-edge-repair/" title="Read more" >...</a>

Top